| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.61B | 11.76B | 11.01B | 10.94B | 10.93B | 9.56B |
| Gross Profit | 8.44B | 6.83B | 7.92B | 7.68B | 7.82B | 6.91B |
| EBITDA | 6.13B | 5.21B | 7.20B | 7.08B | 7.26B | 6.40B |
| Net Income | 1.42B | 1.61B | 2.81B | 2.72B | 2.59B | -1.54B |
Balance Sheet | ||||||
| Total Assets | 234.73B | 234.97B | 231.45B | 226.54B | 238.03B | 224.75B |
| Cash, Cash Equivalents and Short-Term Investments | 7.48B | 10.82B | 6.34B | 5.79B | 9.14B | 6.79B |
| Total Debt | 49.56B | 58.06B | 50.97B | 46.25B | 46.22B | 39.10B |
| Total Liabilities | 80.75B | 82.28B | 76.54B | 71.33B | 73.54B | 65.41B |
| Stockholders Equity | 97.65B | 95.78B | 94.36B | 92.82B | 95.84B | 92.11B |
Cash Flow | ||||||
| Free Cash Flow | 1.74B | 5.04B | 3.91B | 378.00M | -1.14B | -546.00M |
| Operating Cash Flow | 3.69B | 5.21B | 4.02B | 3.10B | 1.74B | 2.58B |
| Investing Cash Flow | -3.13B | -3.07B | -2.85B | -3.20B | -1.44B | -2.21B |
| Financing Cash Flow | -455.00M | 2.38B | -566.00M | -4.25B | 1.82B | 2.06B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$22.92B | 16.73 | 1.48% | 5.62% | -9.78% | -29.50% | |
70 Outperform | HK$150.66B | 24.98 | 1.89% | 6.20% | -19.91% | -6.92% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
53 Neutral | HK$12.08B | -6.69 | -3.35% | 5.93% | 1.37% | -157.43% | |
49 Neutral | HK$2.02B | -3.92 | -1.67% | ― | -21.25% | 24.06% | |
48 Neutral | HK$28.64B | -1.76 | -9.54% | ― | -40.92% | -42.67% |
Hang Lung Group Limited has released its 2025 annual results, providing shareholders and the market with a detailed review of operations, consolidated financial statements and accompanying notes, along with other corporate information. The publication of these results offers investors greater transparency into the company’s financial health and operational performance, which will help inform assessments of its positioning and prospects within Hong Kong’s property and capital markets.
The most recent analyst rating on (HK:0010) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Hang Lung Group stock, see the HK:0010 Stock Forecast page.
Hang Lung Group Limited has announced a proposed final ordinary cash dividend of HKD 0.65 per share for the financial year ended 31 December 2025, subject to shareholder approval at its meeting on 30 April 2026. The dividend will be paid in Hong Kong dollars, with an ex-dividend date of 6 May 2026, a record date of 8 May 2026, and payment scheduled for 15 June 2026, signaling the company’s continued commitment to returning cash to shareholders and providing visibility on income for investors.
The most recent analyst rating on (HK:0010) stock is a Hold with a HK$17.50 price target. To see the full list of analyst forecasts on Hang Lung Group stock, see the HK:0010 Stock Forecast page.
Hang Lung Group Limited has scheduled a board meeting for January 30, 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025. At the same meeting, the board will also consider recommending a final dividend, a decision that could affect shareholder returns and signal management’s view of the group’s financial performance and outlook.
The most recent analyst rating on (HK:0010) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Hang Lung Group stock, see the HK:0010 Stock Forecast page.
Hang Lung Group has announced the planned retirement of Mr. Weber W.P. Lo, its Chief Executive Officer and Executive Director, effective on or before August 31, 2026. The Boards have begun a thorough search for a successor to ensure a seamless leadership transition, acknowledging Mr. Lo’s significant contributions to the organization. This leadership change reflects the company’s focus on continuity and future growth, with implications for its operational strategy and long-term governance structure.
The most recent analyst rating on (HK:0010) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Hang Lung Group stock, see the HK:0010 Stock Forecast page.